PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls
1. PepGen temporarily pauses Phase 2 study to evaluate previous cohort results. 2. Data from the 10 mg/kg cohort expected in Q3 2025. 3. No new safety issues reported since January 2025 update. 4. Focus shifts towards completing CONNECT1 and advancing FREEDOM studies. 5. PEPG stock down 21% at $2.22 following announcement.